Horizon Discovery Group PLC is active in the healthcare market in the United Kingdom. It is one of the leading companies in the application of gene editing and building cells that harbor the genetics of human disease. The company's operating segment includes Screening; Research Reagents; Diagnostics; BioProduction and Base Editing. It generates maximum revenue from the Research Reagents segment. Research Reagents segment revenues arise from the sales of off-the-shelf cell models, bespoke cell engineering services and custom-made and off-the-shelf gene modification and gene editing reagents.
